Skip to main content

Table 1 Baseline characteristics of patients with HER2+ and TNBC breast cancer according to MRI response

From: Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study

 

GSH-YCC (discovery cohort)

AMC-SMC (validation cohort)

Variables

Non-complete MRI responders (N = 151)

Complete MRI responders (N = 30)

Total (N = 181)

P value

Non-complete MRI responders (N = 219)

Complete MRI responders (N = 47)

Total (N = 266)

P value

Age at diagnosis, y

0.760

   

0.102

< 50

100 (66.2)

19 (63.3)

119 (65.7)

88 (40.2)

25 (53.2)

113 (42.5)

≥ 50

51 (33.8)

11 (36.7)

62 (34.3)

131 (59.8)

22 (46.8)

153 (57.5)

Subtype

0.324

   

0.398

HER2+

65 (43.0)

10 (33.3)

75 (41.4)

122 (55.7)

23 (48.9)

145 (54.5)

TNBC

86 (57.0)

20 (66.7)

106 (58.6)

97 (44.3)

24 (51.1)

121 (45.5)

Pathologically confirmed lymph nodea

0.501

   

0.682

Yes

96 (63.6)

21 (70.0)

117 (64.6)

196 (89.5)

43 (91.5)

239 (89.8)

No

55 (36.4)

9 (30.0)

64 (35.4)

23 (10.5)

4 (8.5)

27 (10.2)

Removed lymph nodeb

16 (10–38)

13 (10–28)

15 (10–38)

0.015

10 (5–34)

10 (5–31)

10 (5–34)

0.993

Histologic gradec

0.108

    

1 or 2

68 (62.4)

14 (82.4)

82 (65.1)

   

3

41 (37.6)

3 (17.6)

44 (34.9)

   

Ki-67a

0.861

    

< 14%

34 (27.9)

6 (26.1)

40 (27.6)

   

≥ 14%

88 (72.1)

17 (73.9)

105 (72.4)

   

Clinical T stage

0.040

   

0.015

1

4 (2.7)

3 (10.0)

7 (3.9)

4 (1.8)

4 (8.5)

8 (3.0)

2

95 (62.9)

22 (73.3)

117 (64.6)

147 (67.1)

24 (51.1)

171 (64.3)

≥ 3

52 (34.4)

5 (16.7)

57 (31.5)

68 (31.1)

19 (40.4)

87 (32.7)

Clinical N stage

0.945

   

0.320

1

100 (66.2)

19 (63.3)

119 (65.7)

147 (67.1)

28 (59.6)

175 (65.8)

2

15 (9.9)

3 (10.0)

18 (9.9)

20 (9.1)

3 (6.4)

23 (8.6)

3

36 (23.8)

8 (26.7)

44 (24.3)

52 (23.7)

16 (34.0)

68 (25.6)

Breast operation

0.042

   

0.095

Breast-conserving surgery

70 (46.4)

20 (66.7)

90 (49.7)

99 (45.2)

15 (31.9)

114 (42.9)

Mastectomy

81 (53.6)

10 (33.3)

91 (50.3)

120 (54.8)

32 (68.1)

152 (57.1)

Neoadjuvant systemic therapy regimen

0.373

   

0.081

Chemotherapy

86 (57.0)

20 (66.7)

106 (58.6)

97 (44.3)

24 (51.1)

121 (45.5)

Chemotherapy + Trastuzumab

27 (17.9)

6 (20.0)

33 (18.2)

103 (47.0)

15 (31.9)

118 (44.4)

Chemotherapy + Trastuzumab + Pertuzumab

38 (25.2)

4 (13.3)

42 (23.2)

19 (8.7)

8 (17.0)

27 (10.2)

  1. Data are reported as the number (percentage) of patients unless otherwise indicated
  2. MRI magnetic resonance imaging, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer
  3. aPatients with non-pathologically confirmed lymph nodes and radiologically suspicious lymph nodes are included, and nodal staging work-up is assessed using multiple imaging studies
  4. bData are reported as the number (range) of removed axillary lymph nodes
  5. cMissing values. However, these values have not been assessed in the validation cohort
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us